Articles

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

CHRU Montpellier, UMR-CNRS 5235, Université de Montpellier, France
F. Hoffmann-La Roche Ltd, Basel, Switzerland
CHRU Lille, Unité GRITA, Université de Lille, France
Hospices Civils de Lyon, Université Claude Bernard, France
Genentech, South San Francisco, CA, USA
F. Hoffmann-La Roche Ltd, Basel, Switzerland
Roche Pharmaceutical Research and Early Development, Roche Innovation Center Welwyn, UK
Vol. 101 No. 2 (2016): February, 2016 https://doi.org/10.3324/haematol.2015.133421